Company Overview

Jefferies Healthcare Conference

6th June 2017

Revolutionizing Medicine Through Genome Editing

This presentation contains forward-looking statements as defined in

the Private Securities Litigation Reform Act of 1995, as amended.

All statements contained in this presentation other than statements

of historical facts are forward-looking statements. The words

‘‘anticipate,’’ ‘‘believe,’’ ‘‘continue,’’ ‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’

‘‘intend,’’ ‘‘may,’’ ‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’ ‘‘target,’’

‘‘should,’’ ‘‘would,’’ and similar expressions are intended to identify

forward-looking statements, although not all forward-looking

statements contain these identifying words. These statements relate

to the Company’s strategy, intellectual property position, future

operations, future financial position, potential revenue, projected

costs, prospects, plans, objectives of management and expected

market growth, and involve known and unknown risks, uncertainties

and other factors that may cause the Company’s actual results,

levels of activity, performance or achievements to be materially

different from any future results, levels of activity, performance or

achievements expressed or implied by these forward-looking

statements.

The Company has based these forward-looking statements on

management’s current expectations, assumptions, estimates and

projections. While the Company believes these expectations,

assumptions, estimates and projections are reasonable, such

forward-looking statements are only predictions and involve known

and unknown risks, uncertainties and other important factors, many

of which are beyond the Company’s control and may cause actual

results, performance or achievements to differ materially from those

expressed or implied by any forward-looking statements. These

risks and uncertainties include, without limitation, risks and

uncertainties related to the initiation, timing, progress and results of

the Company’s research and development programs and future

preclinical and clinical studies; the Company’s ability to develop

viable product candidates, achieve regulatory approval for any such

product candidate, or market and sell any product candidates; the

Company’s ability to advance its therapeutic delivery capabilities;

the timing or likelihood of regulatory filings and approvals; the timing

or likelihood of any potential commercialization of the Company’s

product candidates, if approved; the pricing and reimbursement of

the Company’s product candidates, if approved; negative public

opinion and increased regulatory scrutiny of gene editing therapies

and the related effects on public perception and the Company’s

ability to obtain regulatory approval for its product candidates; the

implementation of the Company’s business model, including

strategic plans for the Company’s business, product candidates and

technology; the scope of protection the Company is able to establish

and maintain for intellectual property rights covering the Company’s

product candidates and technology; potential third-party claims of

intellectual property infringement against the Company, its licensors

or its collaborators; the Company’s needs for additional financing;

the Company’s ability to establish, maintain and execute under

strategic collaborations and other third-party arrangements; the

Company’s financial performance; and developments relating to the

Company’s competitors and the Company’s industry.

These and other risks and uncertainties are described in greater

detail under “Risk Factors” section of the Company’s Annual Report

on Form 10-K, which is on file with the U.S. Securities and

Exchange Commission (SEC), and in other filings that the Company

may make with the SEC in the future. The forward-looking

statements in this presentation are made only as of the date hereof,

and except as required by law, the Company undertakes no

obligation to update any forward-looking statements contained in

this presentation as a result of new information, future events or

otherwise.

2

Intellia Therapeutics Legal Disclaimers

3

Accelerating The Development of Life Transforming

Therapies

Breakthrough Scientific

Discovery for DNA Editing

Potentially Curative

One-Time Treatment

Revolutionizing Medicine – New

Tx Paradigm

Treating Underlying

Genetic Cause of Disease

Curative Potential – Single or Limited

Dosing Paradigm

Personalized Genetic Approach

Targets the Underlying Genetic Driver of

Disease

Broad Application – Mono or Polygenic

Diseases

Scalable For Large Patient Populations

Intellia’s Approach

Genome Editing

4

Revolutionizing Medicine Through Genome EditingCurrent Therapeutic Modalities Do Not Treat Underlying Genetic Cause of Disease

Mostly Palliative Not Curative

Non-Personalized Approach

Multiple or Chronic Dosing Regimens

Does Not Address Underlying Genetic Cause of Disease

Current Standard of Care

SmallMolecules

Biologics Gene Therapy

Evolution of Medicine

CRISPR/Cas9: The Ideal Genome Editing Technology

CRISPR/Cas9 ZFN TALEN

Targeting Mechanism RNA Protein Protein

Targeting Site 22bp 18-36bp 30-40bp

Size of Components Small Smaller Large

Engineering Difficulty Minimal High High

Targeting Efficacy High Moderate Moderate

Multiplex Capability? Yes Difficult Difficult

5

Benefits of Using CRISPR

High Cleavage Efficiency

Easy to Engineer

High Selectivity

Rapid Scalability

Simple Optimization

Process

Efficient Path to Proof-of-

Concept

Broad TxApplicability

Multiplex Opportunity

CRISPR/Cas9

Targeting Mechanism RNA

Targeting Site ~18-24bp

Size of Components Smaller

Re-Targeting Difficulty Low

Targeting Efficiency High

Multiplex Capability Easy

Natural System

Potential Single

Curative Treatment

Multiple Genome Editing ApproachesAddressing the Underlying Genetic Driver of Disease

6

Disease Defined DNA Editing

Cas9/RNA

Permanent Modifications

X

Non-Permanent Modifications

InsertionInsert new DNA

sequence to manufacture

therapeutic protein

RepairCorrection of “misspelled”

disease driving DNA sequence

KnockoutInactivation/deletion of disease causing

DNA sequence

CRISPRa(Activation)

Transient activation of DNA sequence

expression

CRISPRi(Inhibition)

Transientinactivation of targeted DNA

expression

e.g. ATTR, HBV, AATD e.g. AATD, IEMs e.g. IEMs

Current Focus Future Potential

7

Broad Platform to Accelerate Therapeutic Development: Expansion Ready

Diversified Pipeline

First company to demonstrate, with a single dose in an animal model, ~97% reduction of serum TTR protein levels using CRISPR/Cas9

Proprietary Delivery Approach

Scalable Application

Commercial

RightsPrograms Type of Edit

Hematopoietic Stem Cells (HSCs)

KnockoutRepair

Insertion

Chimeric Antigen Receptor T Cell (CAR-T)

KnockoutInsertion

Immuno-OncologyKnockoutInsertion

Autoimmune and Inflammatory Diseases (AIID)

KnockoutInsertion

Ex Vivo In Vivo

Commercial Rights

Sentinel Indications Type of Edit

Transthyretin Amyloidosis (ATTR)

Knockout

Hepatitis B Virus (HBV) Knockout

Alpha-1 AntitrypsinDeficiency (AATD)

KnockoutRepair

IEM – Initial focus on Primary Hyperoxaluria Type 1 (PH-1)

KnockoutRepair

Insertion

Diversified Approach Maximizes CRISPR PotentialCapturing Both Ex Vivo and In Vivo Opportunities

* Intellia division 8

*

Attributes: Proprietary Lipid Nanoparticle Delivery System

9

Lipid Nanoparticles (LNPs)

Adeno-Associated Virus (AAV)

Effective Targeting

Broad in vivo

Application via infusion

Transient Expression

Synthetic Scalable

Manufacturing

Efficient delivery &

robust expression

Limited capacity for

delivery

Vector can persist for

years

Immunogenic potential

• Natural affinity to liver

• Potential to be modified to target other organs

• Option to redose if necessary

• Ideal for systemic and local dosing

• Favorable safety profile

• Metabolic clearance of LNP and cargo

ensures transience

• Simple chemical nature limits immunogenicity

• Standard chemical manufacturing

• Straightforward specifications

Diverse Lipid Library for Cas9 Delivery

0 sites28%

1 sites18%

2 sites14%

3 sites10%

4 sites7%

≥ 5 sites23%

10

High Rate of Specific CRISPR/Cas Guides

• >25% of highly-active guides

have no detectable off-target

cutting

• Combining informatic guide selection with

accurate off-target assessment enables

identification of guides with no off-target activity

Human therapeutic liver target sgRNAs

• On-Target

• Off-TargetE

MX

1V

EG

FA

2

No Identified Off-Target Activity

Cu

ttin

g fre

qu

en

cy 10,000

1,000

100

10

1

Long Term Strategic ApproachMaximize Potential To Develop Liver Therapies & Leverage Insights to Expand to Other

Organs and Disease States

11

ATTR

HBVAATD

PH-1

Liver

LIVER

The liver is a target-rich opportunity and also provides important clinical insights that allow for expansion into additional organs and disease states

Expanding Beyond the Liver Liver Indications Provide Insights for Pipeline Expansion

12

Initial focus on 2-3 proprietary liver indications with

unmet need, generating foundational preclinical data

Rapid expansion into other liver indications & edit types

Data from our R&D & delivery evaluation informs continued pipeline expansion

In vivo franchise expansion into other organs including eye, CNS & muscle directly, or indirectly, through business development

Initial Validation in ATTR: Rare Liver Disease

13

Hereditary Transthyretin Amyloidosis

Accumulation of toxic protein –cardiovascular (FAC) & neuronal (FAP) phenotypes

50,000 ATTR patients worldwide, over 100 reported TTRmutations

Onset ~20-70 years, typically fatal within 2-15 years

Current standard of care severely limited

ATTR

Genome Edit

Knockout of TTR gene

Delivery Mechanism

LNP delivery to hepatocytes

Biomarker Readout

Circulating plasma TTR

Intellia’s Approach

High Knockdown & Edit Efficiency After One DoseFirst To Show ~97% TTR Knockdown in vivo Using CRISPR/Cas9

14

~97% Decrease in Serum TTR ~70% Editing of TTR Gene in Liver

High liver editing efficiency after one dose

Editing almost completely stops TTR protein production

Undetectable Cas9 messenger RNA (mRNA) and guide RNA (gRNA) in the liver at 72 hours post administration

Results That Empower Future Development

Concentr

ation (

ng/m

g)

0 .0 0 .2 0 .4 0 .6 0 .8 1 .0

0 .0 0 1

0 .0 1

0 .1

1

1 0

1 0 0

1 0 2 0 3 0

L iv e r C a s 9 + G 2 0 9

T im e (h o u rs )

Co

nc

en

tra

tio

n (

ng

/mg

liv

er)

C a s 9

G 209

0 .0 0 .2 0 .4 0 .6 0 .8 1 .0

0 .0 0 1

0 .0 1

0 .1

1

1 0

1 0 0

1 0 2 0 3 0

L iv e r C a s 9 + G 2 0 9

T im e (h o u rs )

Co

nc

en

tra

tio

n (

ng

/mg

liv

er)

C a s 9

G 209

Time (h)

Rapid Clearance of Cargo In Liver

3 m

pk

1 m

pk

0.3

mpk

0

20

40

60

80

Liver Editing1 Week Post-Dose Cohort

% E

ditin

g

3 m

pk

1 m

pk

0.3

mpk

0

50

100

150

200

Serum TTR

% o

f p

re-d

os

e T

TR

15

Liver Editing Durable at Least 6 MonthsLow Serum TTR Levels Persist

Durable and stable liver editing for at least6 months

Ongoing study (1 year duration)

Stem cell editing may drive durability

Cas9 Expression Is Transient, With Durable Editing Effect

High Durability In Vivo After Single DosePersistent Effect for at Least 6 Months in Ongoing Study

Edited Liver Cell Population Linked To Durability

GS (Glutamine Synthetase)

mRNA Delivered by LNP

3 mpk

1 mpk

0.3 mpk

16

G531 G533 G534 G531 G533 G534

• Sprague Dawley rats

• Single administration

• 7 day time point

Dose Responsive Editing in Rat LiverUp to 66% liver editing and 91% reduction serum TTR

Low Serum TTR Levels Liver Editing

Maximizing Future Opportunities in Other IndicationsPursuing CRISPR’s Application in Other Diseases

17

HBV Intellia’s Approach

240 million chronic HBV patients worldwide, leading cause of liver cirrhosis & cancer

Current standard of care controls viral replication but rarely eradicates virus

Knockout viral covalently closed circular DNA (cccDNA)

Potential to cure disease through eradication of viral DNA

Multiple potential therapeutic applications through HSC editing

Relatively low quantity of available stem cells for treatment

Deliver CRISPR/Cas9 ex vivo

Ex vivo edited target genes & re-engraftment

HSCs Intellia’s Approach

• Over 400 guides screened against the HBV genome in HepAD38 cells

• Editing hotspots observed in the HBV genome

• Targeted genomic disruption induces fetal hemoglobin expression

0 2 5 5 0 7 5 1 0 0 1 2 5 1 5 0 1 7 5 2 0 0 2 2 5 2 5 0 2 7 5 3 0 0 3 2 5 3 5 0 3 7 5 4 0 0 4 2 5

0

1 0

2 0

3 0

4 0

5 0

6 0

7 0

8 0

9 0

1 0 0

%

Ed

itin

g

Guide Reference #

Induction of HbF Cells

% a

lle

lic e

ditin

g

100

control Lead guide 1

Lead guide 2

80

60

40

20

0

CD34+ HSPC Gene Editing

0

control Lead guide 1

Lead guide 2

% H

bF

+ c

ells

(backgro

und

subtr

acte

d)

30

20

10

* *

Mean ± S.D., n=3

*P<0.001 one way ANOVA with Dunnett’s post hoc test versus Mock

Induction of HbF Cells

% a

lle

lic e

ditin

g

100

control Lead guide 1

Lead guide 2

80

60

40

20

0

CD34+ HSPC Gene Editing

0

control Lead guide 1

Lead guide 2

% H

bF

+ c

ells

(backgro

und

subtr

acte

d)

30

20

10

* *

Ex V

ivo

In V

ivo

Differentiated Partnership StrategyEnhances Intellia’s R&D Capabilities and Pipeline Growth

18

Multi-year initial collaboration

Product-focused discovery for CAR-Ts and HSCs

Draft pick process for HSC targets

Multi-year initial collaboration

Up to 10 in vivo targets

Two component deal

Liver-centric product development

Platform development

Partnership with leading pharmaceutical company

ATTR first selected co-co target

Intellia access to:

Regeneron Genetics Center

Animal model development

Tools & reagents

Compelling economics

Up to $320M milestones per target

High single-digit to low-teen royalties

$75M upfront

$50M equity investment

Co-development and commercialization options

Compelling economics

Up to $230M in milestone payments per product

Mid single-digit royalties

Up to $50M in committed collaboration funding

$18M equity investment

Leading CAR-T & HSC pharma provides near term access to CAR-T & HSC development

Access to:

LNP library utilized in in vivoprogram

HSC expansion technology utilized in ex vivo program

Regulatory & manufacturing expertise

Ex V

ivo

In V

ivo

19

Intellia Enters Research Collaboration:To Generate Genome-Edited Cell Therapies for Cancer

• 3-year research collaboration with Ospedale San Raffaele, Milan, Italy under

the direction of Professor Chiara Bonini

– Prof. Bonini is the Head of San Raffaele’s Experimental Hematology Unit and

Deputy Director of the Division of Immunology, Transplantation and Infectious

Diseases

• Research collaboration harnesses Intellia’s CRISPR/Cas9 genome editing

technology to engineer improved T-cell therapies targeting unmet needs in

hematological and solid tumors

• This agreement marks the first external partnership for eXtellia

– eXtellia, a division of Intellia, was established in 2016 and has identified its initial

areas of focus as immuno-oncology and auto-immunity

– eXtellia’s strategy is focused on advancing new generations of engineered cell

therapies through unique and proprietary applications of CRISPR genome editing

20

Intellia-Developed or Licensed IP

• LNP for delivering CRISPR/Cas9

• Chemically modified guide RNA

• Program-specific IP

• Analytical methods

• Alternative Cas9

Current and future CRISPR/Cas9-

related IP for human therapeutics

Collaboration IP

• Program-specific IP

• Platform improvements

LNP and HSC Technology;

Collaboration IP

• CAR-T program IP

• HSC program IP

• Platform improvements

UCal/Vienna/Charpentier IP

Intellia sublicenses U Cal / U Vienna’s

rights:

• CRISPR/Cas9 for genome editing

• Claims allowed or granted in multiple

jurisdictions

Caribou-Developed IP

Portfolio includes:

• Cas9 guide variants

• Cas9 protein variants

Other In-Licensed IP

Includes:• DuPont CRISPR-Cas9 IP • Vilnius IP

Leading Intellectual Property Position

Building Broad IP Portfolio Across Product Continuum Enables Intellia to Capture Greater Market Opportunity

21

Intellia’s global IP strategy positions for strong protection beyond the Platform IP

Site specific nuclease technology

LNP and other delivery methods for editing cargo

Structural & chemical modifications of guide RNAs

Scale-up, purification & analytics

Indication-specific patents

PreclinicalAsset

CommercialProduct

Final product composition

R&D Programs & Pipeline*

22

ProgramsCommercial

RightsType of Edit Delivery Status Comments

In V

ivo

Transthyretin Amyloidosis

(ATTR)Knockout LNP

• 2017 NHP Studies

Hepatitis B Virus

(HBV)Knockout LNP

Alpha-1 Antitrypsin Deficiency

(AATD)

Knockout

RepairLNP

Inborn Errors of Metabolism Primary Hyperoxaluria (PH-1)

Knockout

Repair

Insertion

LNP

Ex V

ivo

Hematopoietic Stem Cells

(HSC)

Knockout

Repair

Insertion

Electroporation

Chimeric Antigen Receptor

T Cells (CAR-T)

Knockout

InsertionElectroporation

Late Stage Preclinical

Development

Preclinical

Development

• 2017 Positioned to

commence animal

model studies

Commencing

NHP Studies

In vitro Guide

Evaluation

Guide Design

& Evaluation

Guide Design

& Evaluation

• 2H17 - 1H18

IND-Enabling Studies

* The table sets identify Intellia’s (including collaboration) principal discovery programs and pipeline opportunities as of March 31, 2017

23

Investment ThesisAccelerating the Development of LifeTransforming Therapies

Industry Leader

Robust, Global IP Strategy

Committed Partnerships

Proprietary Delivery System

Strong Balance Sheet

Diversified Pipeline

Nasdaq: NTLA

www.intelliatx.com